- Home
- PSHG vs NOTV Comparison
PSHG vs NOTV Comparison
Compare PSHG & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- NOTV
- Stock Information
- Founded
- PSHG 2010
- NOTV 1974
- Country
- PSHG Greece
- NOTV United States
- Employees
- PSHG N/A
- NOTV N/A
- Industry
- PSHG Marine Transportation
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- NOTV Health Care
- Exchange
- PSHG Nasdaq
- NOTV Nasdaq
- Market Cap
- PSHG 26.9M
- NOTV 28.7M
- IPO Year
- PSHG N/A
- NOTV 1997
- Fundamental
- Price
- PSHG $2.05
- NOTV $0.87
- Analyst Decision
- PSHG
- NOTV Strong Buy
- Analyst Count
- PSHG 0
- NOTV 1
- Target Price
- PSHG N/A
- NOTV $5.00
- AVG Volume (30 Days)
- PSHG 132.9K
- NOTV 1.6M
- Earning Date
- PSHG 11-25-2025
- NOTV 12-03-2025
- Dividend Yield
- PSHG N/A
- NOTV N/A
- EPS Growth
- PSHG N/A
- NOTV N/A
- EPS
- PSHG 1.33
- NOTV N/A
- Revenue
- PSHG $79,691,000.00
- NOTV $505,299,000.00
- Revenue This Year
- PSHG N/A
- NOTV $5.64
- Revenue Next Year
- PSHG $17.95
- NOTV $5.16
- P/E Ratio
- PSHG $1.49
- NOTV N/A
- Revenue Growth
- PSHG N/A
- NOTV 0.85
- 52 Week Low
- PSHG $1.31
- NOTV $0.66
- 52 Week High
- PSHG $2.34
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- PSHG 49.24
- NOTV 36.75
- Support Level
- PSHG $1.97
- NOTV $0.77
- Resistance Level
- PSHG $2.24
- NOTV $0.86
- Average True Range (ATR)
- PSHG 0.11
- NOTV 0.13
- MACD
- PSHG -0.02
- NOTV -0.01
- Stochastic Oscillator
- PSHG 38.89
- NOTV 35.07
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.